BlackRock voting rights attached to shares in ChemoMetec rose to 15.08% on October 26, 2026, exceeding a 15% disclosure threshold, the Danish company said. BlackRock’s combined voting-rights position remained unchanged at 15.08%.

BlackRock voting rights by holding type

ChemoMetec said on October 28 that BlackRock had notified it of the increase in voting rights attached to shares. At the same time, BlackRock’s voting rights attached to financial instruments fell to 0.00%.

The announcement identifies a change in the composition of BlackRock’s position, rather than an increase in its aggregate voting rights. It does not specify the transactions behind the change.

Why the threshold matters

The Danish major-shareholder notification rules include a 15% threshold and require qualifying shareholders to notify the company and regulator when holdings reach, exceed or fall below specified levels.

ChemoMetec, which is listed in Copenhagen, develops and markets cell-counting and other measurement instruments for pharmaceutical, biotechnology and agricultural customers.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.